FORESIGHT-DX.COM: Keyword Density Checker

Total words: 578 | 2-word phrases: 148 | 3-word phrases: 152 | 4-word phrases: 154

PAGE INFO

Title	Try to keep the title under 60 characters (28 characters) Home \| Foresight Diagnostics
Description	Try to keep the meta description between 50 - 160 characters (168 characters) Foresight Diagnostics make the world’s most sensitive ctDNA/cfDNA liquid biopsy minimal residual disease (MRD) test that detects the earliest hints of cancer relapse.
Keywords	Meta keywords are not recommended anymore (0 characters)
H1	H1 tag on the page (27 characters) See clearly.Act decisively.

#	Keyword	Frequency	Density
1	foresight diagnostics	5	3.38%
2	investigating cemacabtagene	2	1.35%
3	of first	2	1.35%
4	part of	2	1.35%
5	as part	2	1.35%
6	product as	2	1.35%
7	t product	2	1.35%
8	car t	2	1.35%
9	an allogeneic	2	1.35%
10	diagnostics logo	2	1.35%
11	ansegedleucel cemacel	2	1.35%
12	trial investigating	2	1.35%
13	treatment for	2	1.35%
14	phase 2	2	1.35%
15	pivotal phase	2	1.35%
16	initiates pivotal	2	1.35%
17	allogene therapeutics	2	1.35%
18	foresight clarity	2	1.35%
19	by roche	2	1.35%
20	filed by	2	1.35%

#	Keyword	Frequency	Density
1	foresight diagnostics logo	2	1.32%
2	car t product	2	1.32%
3	treatment for patients	2	1.32%
4	line treatment for	2	1.32%
5	part of first	2	1.32%
6	as part of	2	1.32%
7	product as part	2	1.32%
8	t product as	2	1.32%
9	cemacel an allogeneic	2	1.32%
10	patients with large	2	1.32%
11	trial investigating cemacabtagene	2	1.32%
12	pivotal phase 2	2	1.32%
13	initiates pivotal phase	2	1.32%
14	filed by roche	2	1.32%
15	lawsuit filed by	2	1.32%
16	meritless lawsuit filed	2	1.32%
17	to meritless lawsuit	2	1.32%
18	for patients with	2	1.32%
19	ansegedleucel cemacel an	2	1.32%
20	bcell lymphoma lbcl	2	1.32%
21	lymphoma lbcl likely	2	1.32%
22	lbcl likely to	2	1.32%
23	large bcell lymphoma	1	0.66%
24	diagnostics foresight diagnostics	1	0.66%
25	jul 02 2024	1	0.66%
26	roche jul 02	1	0.66%
27	by roche jul	1	0.66%
28	27001 cert no	1	0.66%
29	cert no c1342isms4981221	1	0.66%
30	team careers contact	1	0.66%

#	Keyword	Frequency	Density
1	ansegedleucel cemacel an allogeneic	2	1.30%
2	lymphoma lbcl likely to	2	1.30%
3	car t product as	2	1.30%
4	t product as part	2	1.30%
5	product as part of	2	1.30%
6	as part of first	2	1.30%
7	line treatment for patients	2	1.30%
8	treatment for patients with	2	1.30%
9	for patients with large	2	1.30%
10	lawsuit filed by roche	2	1.30%
11	to meritless lawsuit filed	2	1.30%
12	bcell lymphoma lbcl likely	2	1.30%
13	meritless lawsuit filed by	2	1.30%
14	initiates pivotal phase 2	2	1.30%
15	diagnostics logo technology partnership	1	0.65%
16	therapeutics initiates pivotal phase	1	0.65%
17	allogene therapeutics initiates pivotal	1	0.65%
18	by roche allogene therapeutics	1	0.65%
19	filed by roche allogene	1	0.65%
20	02 2024 foresight diagnostics	1	0.65%
21	jul 02 2024 foresight	1	0.65%
22	what others miss latest	1	0.65%
23	updates jul 03 2024	1	0.65%
24	jul 03 2024 invalidation	1	0.65%
25	diagnostics foresight diagnostics responds	1	0.65%
26	responds to meritless lawsuit	1	0.65%
27	by roche jul 02	1	0.65%
28	filed by roche jul	1	0.65%
29	2024 invalidation of two	1	0.65%
30	invalidation of two personalis	1	0.65%
31	of two personalis patents	1	0.65%
32	two personalis patents in	1	0.65%
33	pivotal phase 2 trial	1	0.65%
34	settlement with foresight diagnostics	1	0.65%
35	with foresight diagnostics foresight	1	0.65%
36	foresight diagnostics foresight diagnostics	1	0.65%
37	roche jul 02 2024	1	0.65%
38	foresight diagnostics logo technology	1	0.65%
39	phase 2 trial investigating	1	0.65%
40	lbcl likely to relapse	1	0.65%

#	URL	Whois	Check
1	https://foresight-dx-21701857.hs-sites.com/investigator-initiated-research-screening-form	Whois	hs-sites.com